|
Black HR, Elliott WJ, Grandits G, Gramsch P, CONVINCE Research Group, et al. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by georgraphical region. Journal of Hypertension 23: 1099-1106, No. 5, May 2005 . Rush University Medical Center, Chicago, Illinois, USA
Journal Fulltext. |
|
|
|
 |
|
| Trial Acronym(s): |
|
| CONVINCE (Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints) |
|
|
|
|
|
|
| Design: |
Multicentre, randomised, double-blind |
| Control: |
Baseline comparison, drug comparison, patient comparison, geographical comparison |
| Phase: |
III |
| Location: |
USA, Canada, Spain, United Kingdom, Italy, Sweden, Germany, Bulgaria, Israel, Mexico, Czech Republic, Hungary, Poland, Slovakia, Brazil |
| Endpoints: |
Blood pressure, Cardiovascular death, Cardiovascular events, Diastolic blood pressure, Hospitalisation, Mortality, Myocardial infarction event rate, Patient compliance, Revascularisation, Stroke event rate, Systolic blood pressure |
|
|
|
|
|
|
| No |
Age |
|
| 16476 |
adult, elderly |
|
| Patient Inclusion Criteria: Hypertensive volunteers with at least one or more additional cardiovascular risk factors. |
|
|
|
|
|
| Drug/Treatment |
|
| Atenolol |
|
| Hydrochlorothiazide |
|
| Verapamil |
|
|
|
|
|
Hydrochlorothiazide: therapeutic use
Hypertension: treatment
Verapamil: therapeutic use
Atenolol: therapeutic use |
|
|